These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34304979)

  • 1. Computational investigation of FDA approved drugs as selective PARP-1 inhibitors by targeting BRCT domain for cancer therapy.
    Kumar C; Lakshmi PTV; Arunachalam A
    J Mol Graph Model; 2021 Nov; 108():107919. PubMed ID: 34304979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural studies of the PARP-1 BRCT domain.
    Loeffler PA; Cuneo MJ; Mueller GA; DeRose EF; Gabel SA; London RE
    BMC Struct Biol; 2011 Oct; 11():37. PubMed ID: 21967661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage.
    Masson M; Niedergang C; Schreiber V; Muller S; Menissier-de Murcia J; de Murcia G
    Mol Cell Biol; 1998 Jun; 18(6):3563-71. PubMed ID: 9584196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
    Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A
    Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942
    [No Abstract]   [Full Text] [Related]  

  • 5. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
    Li Y; Liu CF; Rao GW
    Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive look of poly(ADP-ribose) polymerase inhibition strategies and future directions for cancer therapy.
    Kumar C; Rani N; Velan Lakshmi PT; Arunachalam A
    Future Med Chem; 2017 Jan; 9(1):37-60. PubMed ID: 27995810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic inhibitor selectivity between PARP1 and PARP2 enzymes: Molecular implications for ovarian cancer personalized therapy.
    Zuo X; Zhao H; Li D
    J Mol Recognit; 2021 Jul; 34(7):e2891. PubMed ID: 33684965
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Kam CM; Tauber AL; Oosthuizen DL; Levonis SM; Schweiker SS
    Future Med Chem; 2020 Dec; 12(23):2105-2122. PubMed ID: 33225737
    [No Abstract]   [Full Text] [Related]  

  • 9. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
    Dulaney C; Marcrom S; Stanley J; Yang ES
    Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly(ADP-ribose) polymerase-1 activation during DNA damage and repair.
    Dantzer F; Amé JC; Schreiber V; Nakamura J; Ménissier-de Murcia J; de Murcia G
    Methods Enzymol; 2006; 409():493-510. PubMed ID: 16793420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
    Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy.
    Cepeda V; Fuertes MA; Castilla J; Alonso C; Quevedo C; Soto M; Pérez JM
    Recent Pat Anticancer Drug Discov; 2006 Jan; 1(1):39-53. PubMed ID: 18221025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy.
    Wang YQ; Wang PY; Wang YT; Yang GF; Zhang A; Miao ZH
    J Med Chem; 2016 Nov; 59(21):9575-9598. PubMed ID: 27416328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP inhibitors for cancer therapy.
    Curtin NJ
    Expert Rev Mol Med; 2005 Mar; 7(4):1-20. PubMed ID: 15836799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1.
    Schreiber V; Amé JC; Dollé P; Schultz I; Rinaldi B; Fraulob V; Ménissier-de Murcia J; de Murcia G
    J Biol Chem; 2002 Jun; 277(25):23028-36. PubMed ID: 11948190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure based pharmacophore study to identify possible natural selective PARP-1 trapper as anti-cancer agent.
    Kumar C; P T V L; Arunachalam A
    Comput Biol Chem; 2019 Jun; 80():314-323. PubMed ID: 31078910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal structures of the catalytic domain of human PARP15 in complex with small molecule inhibitors.
    Zhou X; Yang Y; Xu Q; Zhou H; Zhong F; Deng J; Zhang J; Li J
    Biochem Biophys Res Commun; 2022 Sep; 622():93-100. PubMed ID: 35843099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
    Li N; Wang Y; Deng W; Lin SH
    Anticancer Agents Med Chem; 2019; 19(2):206-212. PubMed ID: 30417796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Review on DNA Repair Inhibition by PARP Inhibitors in Cancer Therapy.
    Shah AP; Patel CN; Sureja DK; Sanghavi KP
    Folia Med (Plovdiv); 2018 Mar; 60(1):39-47. PubMed ID: 29668451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.